Survodutide vs Retatrutide: Are Two Receptors Enough?
Every year a new molecule emerges promising to revolutionize the fight against obesity. In 2024, Boehringer Ingelheim’s survodutide made headlines with promising Phase 2 results: up to 18.7% weight loss.
Impressive numbers. But there is a detail most media outlets are not telling you.
During the same period, retatrutide — which we call TRIPLE-G on this blog, after its three Gs (GLP-1, GIP, Glucagon) — achieved 24.2% in Phase 2. With a curve that had not yet stopped declining.
The question is not whether survodutide works. It works. The question is: when you have a triple agonist available, does it make sense to stop at two?
Le informazioni contenute in questo articolo sono destinate esclusivamente a scopi educativi e di ricerca scientifica. Non costituiscono consiglio medico, diagnosi o trattamento. Consultare sempre un professionista sanitario qualificato.
What These Molecules Are
Survodutide: The Dual GLP-1/Glucagon Agonist
Survodutide (BI 456906) is a synthetic peptide that activates 2 receptors:
- GLP-1 — reduces appetite, slows gastric emptying, improves insulin secretion
- Glucagon — stimulates hepatic lipolysis (fat breakdown in the liver) and increases thermogenesis
Developed by Boehringer Ingelheim, it is in Phase 3 with the SYNCHRONIZE program (results expected in 2026). Administration is weekly via subcutaneous injection.
The idea is smart: glucagon burns fat, GLP-1 suppresses hunger. Two peptides in one.
TRIPLE-G: The Complete Triple Agonist
Retatrutide (LY3437943), developed by Eli Lilly, does everything survodutide does — and adds a third receptor: GIP (Glucose-dependent Insulinotropic Polypeptide).
Three receptors, three synergistic actions:
- GLP-1 — satiety, glycemic control
- GIP — fat metabolism, insulin sensitivity, adipose distribution
- Glucagon — hepatic lipolysis, thermogenesis, energy expenditure
The Phase 3 program is called TRIUMPH and is currently underway.
For a complete comparison across all three generations of peptides (semaglutide, tirzepatide, retatrutide), read our three-way comparison.
The Numbers: How Much Weight Do You Lose?
The data come from randomized, double-blind, placebo-controlled clinical trials.
| Molecule | Receptors | Study | Max Dose | Duration | Weight Loss |
|---|---|---|---|---|---|
| Survodutide | 2 (GLP-1 + Glucagon) | Phase 2 | 4.8 mg/wk | 46 weeks | -14.9% (mean) |
| Survodutide | 2 | Phase 2 (completers) | 4.8 mg/wk | 46 weeks | -18.7% |
| TRIPLE-G | 3 (GLP-1 + GIP + Glucagon) | Phase 2 | 12 mg/wk | 48 weeks | -24.2% |
| Semaglutide | 1 (GLP-1) | STEP 1 | 2.4 mg/wk | 68 weeks | -15.3% |
| Tirzepatide | 2 (GLP-1 + GIP) | SURMOUNT-1 | 15 mg/wk | 72 weeks | -22.5% |
The survodutide and TRIPLE-G numbers come from Phase 2 studies, with smaller sample sizes than Phase 3 trials. Final results may vary, but the direction is clear.
The difference between survodutide and TRIPLE-G is 5-9 percentage points — a significant margin reflecting the action of the third receptor (GIP).
Why the Third Receptor Changes Everything
Survodutide already has glucagon, so it's almost the same as TRIPLE-G.
Glucagon burns fat in the liver and increases metabolism, but the GIP receptor — absent in survodutide — is responsible for peripheral lipid metabolism, visceral fat redistribution, and insulin sensitivity at the adipose tissue level. It is the missing piece.
GIP is not a minor detail. It is the receptor that:
- Acts directly on adipocytes — the cells that store fat — stimulating lipid release
- Improves insulin sensitivity — not just in the pancreas, but in adipose tissue and muscle
- Modifies fat distribution — promoting the reduction of visceral fat (the most dangerous kind)
- Enhances the effect of GLP-1 — the GLP-1/GIP synergy produces results greater than the sum of individual effects
Without GIP, survodutide achieves results similar to tirzepatide (which has GLP-1 + GIP but not glucagon). With all 3 receptors, TRIPLE-G outperforms both.
Fatty Liver: Survodutide Shines Here (But TRIPLE-G Shines Brighter)
Survodutide has demonstrated remarkable results on metabolic steatohepatitis (MASH). In the Phase 2 trial published in the New England Journal of Medicine in 2024:
- 62% of participants showed MASH improvement without worsening of fibrosis (vs 14% placebo)
- The glucagon component is the key: it directly stimulates beta-oxidation of hepatic fatty acids
But TRIPLE-G performed even better on fatty liver:
- 86% hepatic steatosis resolution in the Phase 2 trial (12 mg dose)
- Liver fat reduction of up to 82.4% from baseline
For fatty liver, survodutide is the best choice because it has glucagon.
TRIPLE-G also has glucagon — plus GIP, which improves systemic lipid metabolism and reduces the visceral fat accumulation that drives steatosis. The data show 86% vs 62% MASH resolution. The triple agonist is superior here as well.
Safety Profile
The most common reactions for both molecules are gastrointestinal: nausea, vomiting, diarrhea. Typical of the entire GLP-1 class.
| Parameter | Survodutide | TRIPLE-G |
|---|---|---|
| Nausea (% of participants) | ~40-45% | ~25-35% |
| Discontinuation due to adverse events | ~7-10% | ~5.6% |
| Severe gastrointestinal reactions | Rare | Rare |
The slightly lower nausea rate with TRIPLE-G may be due to the modulatory effect of GIP, which attenuates the gastrointestinal impact of GLP-1. The same phenomenon is observed with tirzepatide compared to semaglutide.
For a comprehensive guide on managing initial reactions, read our article on how your body responds to GLP-1 peptides.
Development Status and Availability
| Aspect | Survodutide | TRIPLE-G |
|---|---|---|
| Manufacturer | Boehringer Ingelheim | Eli Lilly |
| Phase 3 | SYNCHRONIZE (ongoing) | TRIUMPH (ongoing) |
| Phase 3 results expected | 2026 | 2026-2027 |
| Estimated FDA approval | 2027-2028 | 2026-2027 |
| Research-grade availability | Not yet | Available in Europe |
| Format | Weekly subcutaneous | Lyophilized research-grade |
The Full Picture
Survodutide is a promising molecule. Two receptors are better than one, and the data on fatty liver and weight loss are solid. If approved, it will be a good option for those who do not respond to semaglutide.
But when you put the numbers side by side, the picture is clear:
- Weight loss: TRIPLE-G 24.2% vs Survodutide 14.9-18.7%
- Fatty liver: TRIPLE-G 86% resolution vs Survodutide 62%
- Receptors: TRIPLE-G 3 vs Survodutide 2
- Tolerability: TRIPLE-G slightly better (less nausea)
Survodutide is a step forward from semaglutide. But TRIPLE-G is a generational leap. The difference between having 2 tools and having 3 is not 50% — it is exponential, thanks to receptor synergy.
TRIPLE-G is currently the only triple agonist in the world in advanced clinical development. No other molecule simultaneously activates the GLP-1, GIP, and glucagon receptors.
Scientific References
- Survodutide Phase 2 — Obesity: Lancet Diabetes Endocrinol. 2024. Randomized, double-blind, placebo-controlled trial in 386 adults with BMI ≥27, 46 weeks. DOI: 10.1016/S2213-8587(23)00356-X
- Survodutide Phase 2 — MASH: NEJM 2024. Phase 2 randomized trial of survodutide in MASH and fibrosis. DOI: 10.1056/NEJMoa2401755
- Survodutide Phase 3 Design: SYNCHRONIZE-1 and -2 rationale and design. DOI: 10.1111/dom.15876
- Retatrutide Phase 2: Jastreboff AM et al. NEJM 2023. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. DOI: 10.1056/NEJMoa2301972
- Retatrutide Hepatic: Sanyal AJ et al. NEJM 2024. Retatrutide for MASLD and MASH. DOI: 10.1056/NEJMoa2407043
- Semaglutide STEP 1: Wilding JPH et al. NEJM 2021. DOI: 10.1056/NEJMoa2032183
- Tirzepatide SURMOUNT-1: Jastreboff AM et al. NEJM 2022. DOI: 10.1056/NEJMoa2206038
